Genome-wide CRISPR screens reveal APR-246 (Eprenetapopt) triggers ferroptosis and inhibits iron-sulfur cluster biogenesis
Fujihara, K. M.; Zhang, B. Z.; Jackson, T. D.; Nijagal, B.; Ang, C.-S. M.; Nikolic, I.; Sutton, V.; Trapani, J.; Simpson, K. J.; Stojanovski, D.; Leimkuehler, S.; Haupt, S.; Phillips, W. A.; Clemons, N. J.
Show abstract
The mechanisms by which cells respond and adapt to oxidative stress are largely unknown but are key to developing a rationale for cancer therapies that target antioxidant pathways. APR-246 is a mutant-p53 targeted therapeutic currently under clinical investigation in myeloid dysplastic syndrome (MDS) and acute myeloid leukemia1. Whilst the mechanism of action of APR-246 is thought to be reactivation of wild-type p53 activity through covalent modification of cysteine residues in the core domain of mutant-p53 protein2,3, here we report that the anti-neoplastic capacity of APR-246 lies predominantly in the conjugation of free cysteine. Genome-wide CRISPR perturbation screening, metabolite profiling and proteomics in response to APR-246 treatment in mutant-p53 cancer cells highlighted the role of GSH and mitochondrial metabolism in determining APR-246 efficacy. APR-246 sensitivity was increased through loss of key enzymes in mitochondrial one-carbon metabolism, SHMT2 and MTHFD1L, due to diminished glycine supply for de novo GSH synthesis. Critically, we show that APR-246 induces iron-dependent, apoptotic machinery-independent cell death, ferroptosis. Whole-cell proteomics analyses indicated an upregulation of proteins involved in iron-sulfur cluster biogenesis (eg. FDX1). GSH, acetyl-CoA and NADH levels were also depleted in APR-246 treated cells. Importantly, we found that APR-246 inhibits iron-sulfur cluster biogenesis in the mitochondria of cancer cells through cysteine conjugation. This work not only details novel determinants of APR-246 activity in cancer cells, but also provides a clinical roadmap for targeting antioxidant pathways in tumours - beyond targeting mutant-p53 tumours. O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=104 SRC="FIGDIR/small/398867v1_ufig1.gif" ALT="Figure 1"> View larger version (16K): org.highwire.dtl.DTLVardef@11155f8org.highwire.dtl.DTLVardef@1231cb7org.highwire.dtl.DTLVardef@324881org.highwire.dtl.DTLVardef@136146f_HPS_FORMAT_FIGEXP M_FIG C_FIG
Matching journals
The top 13 journals account for 50% of the predicted probability mass.
Similar papers in this journal
Similar papers in this journal
- Glutamine mimicry suppresses tumor progression through asparagine metabolism in pancreatic ductal adenocarcinoma 95%
- Combined KRASG12C and SOS1 inhibition enhances and extends the anti-tumor response in KRASG12C-driven cancers by addressing intrinsic and acquired resistance 93%
- A sense-antisense RNA interaction promotes breast cancer metastasis via regulation of NQO1 expression 93%
Similar papers in this journal
- Enhancement of colorectal cancer therapy through interruption of the HSF1-HSP90 axis by p53 activation or cell cycle inhibition 94%
- Targeting the mitochondrial RNA methyltransferase TRMT61B reveals new therapeutic opportunities in aneuploid cancer cells 93%
- Targeting TACC3 represents a novel vulnerability in highly aggressive breast cancers with centrosome amplification 93%
Similar papers in this journal
- SLC7A11 is a superior determinant of APR-246 (Eprenetapopt) response than TP53 mutation status 97%
- Repurposing the antidepressant sertraline as SHMT inhibitor to suppress serine/glycine synthesis addicted breast tumor growth. 94%
- Clinical positioning of the IAP antagonist tolinapant (ASTX660) in colorectal cancer 93%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.